Central banks in several countries are holding policy rates steady while inflation pressures remain uneven. That mix keeps bond yields and cash returns uncertain, which makes reliable income from equities more appealing. Dividend Powerhouses can offer regular cash payouts that do not depend on policy meetings every few months. This article walks through 3 stocks from the Dividend Powerhouses screener that currently offer 3%+ yields with a focus on coverage and stability.

The three stocks covered below are just a small sample, since the full Dividend Powerhouses screen surfaced 1,855 more companies with equally compelling income stories that are not covered here. To identify and analyze your own high conviction dividend ideas, head straight into the Dividend Powerhouses (3%+ Yield) screener.

CSL (ASX:CSL)

Overview: CSL is a Melbourne based biopharmaceutical group that collects human plasma and develops vaccines and medicines to treat rare diseases, immune disorders, bleeding conditions, respiratory issues and iron deficiency, selling these therapies to governments and healthcare systems worldwide.

Operations: CSL generates most of its revenue from CSL Behring at about $10.9b, with CSL Vifor contributing around $2.4b and CSL Seqirus about $2.2b.

Market Cap: A$65.4b

CSL may appeal to investors seeking dividend income with exposure to healthcare demand that does not depend on the economic cycle. The core plasma and vaccine businesses rely on an extensive global collection and manufacturing network, and products like ANDEMBRY illustrate how CSL continues to add new therapies to that base. At the same time, earnings are working through a heavy restructuring phase, margins have compressed, debt is sizeable and dividend cover by earnings is currently weak. Analysts project strong earnings growth, but those gains would need to offset these pressures. The key question for investors is whether today’s valuation already reflects those challenges or still underestimates the value of CSL’s core franchise and pipeline.

CSL’s compressed margins and weak dividend cover may be masking where its earnings power could settle once restructuring is bedded down. Get the full context in the 2 key rewards and 4 important warning signs

Build your own dividend healthcare shortlist

CSL and the other two dividend stocks in this list all came from a single screener, but the real advantage is in setting your own rules. Use our flexible Screener to combine filters on dividends, balance sheet strength, valuation and risks, or tap into our curated Investing Ideas for ready made shortlists built around specific themes.

Accenture (ACN)

Overview: Accenture is a Dublin based professional services company that helps large businesses and governments design, build and run their technology, cloud, AI and outsourcing operations, from core IT systems through to finance, HR, supply chains and customer support.

Operations: Accenture generates most of its revenue from its Products segment at about US$22.3b, with Health & Public Service at about US$14.9b, Financial Services at about US$13.8b, Communications, Media & Technology at about US$12.4b and Resources at about US$9.8b.

Market Cap: US$109.2b

Accenture offers a 3.69% dividend yield from a business that sits inside critical technology decisions for around 9,000 large clients, yet the stock trades on a P/E of 13.9x while the market considers the potential impact of AI disruption and softer consulting demand. Earnings and revenue growth forecasts are described as steady rather than exciting, and guidance points to only modest top line momentum. Investors are being paid to wait while the company focuses on AI, cybersecurity and a planned US$9b acquisition program. The catch is that margins have come under pressure, bookings have cooled and a US$865m restructuring highlights the scale of AI transition costs. For dividend focused investors, the question is whether today’s discount fairly reflects those risks or overshoots.

Accenture’s 3.69% yield and 13.9x P/E hint that skepticism about AI and consulting demand might be masking the full story. Scan the analysis report for Accenture to see what the market could be missing next.

Commonwealth Bank of Australia (ASX:CBA)

Overview: Commonwealth Bank of Australia is a large Sydney based bank that provides everyday transaction accounts, savings, mortgages, credit cards, insurance and business banking services to households and companies across Australia, New Zealand and select international markets.

Operations: Commonwealth Bank of Australia generates most of its revenue from Retail Banking Services at about A$13.4b and Business Banking at about A$9.7b, with smaller contributions from New Zealand at about A$3.0b and Institutional Banking and Markets at about A$2.9b.

Market Cap: A$279.5b

Commonwealth Bank of Australia sits at the centre of Australian banking with A$10.9b in net income, a net profit margin above 37% and a fully franked final dividend of A$2.70 per share for 2026. However, the stock trades on an elevated P/E compared with other banks, while forecasts for revenue and earnings growth are relatively modest. Investors are weighing an expensive share price against a franchise with high customer loyalty, strong capital ratios and ongoing AI led cost savings that are already replacing call centre roles. The key issue is whether digital competition, mortgage concentration and softer revenue expectations eventually affect margins or whether CBA’s technology investment and balance sheet strength keep the dividend story on track.

Commonwealth Bank of Australia’s premium valuation and strong dividend profile suggest the full story is not reflected in the headline numbers yet. See how the analyst forecasts for Commonwealth Bank of Australia could reshape expectations around margins and digital competition.

Seeking Fresh Alternatives With Real Potential?

Fresh opportunities do not sit still. While attention stays on today's dividend stocks, other ideas could be building momentum under the radar for now.

• Spot income ideas before they start flying as investors reassess balance sheets using the curated list of solid balance sheet and fundamentals (20 results).
• Explore the next wave of AI momentum by checking companies already generating profits inside the focused 76 profitable AI stocks that aren't just burning cash.
• Prepare for potential changes in commodity sentiment with producers highlighted in the targeted 30 elite gold producer stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.